📊 Backtest📒 Journal Updated 13/08/2026
← 🔥 Turbo
📐 Simulate Position
STALE?Report written 36 days ago · at $11.50entry levels may be stale — re-check before acting

SLN

ค่าขนมSMALL CAP
Silence Therapeutics plc · NASDAQ · Healthcare / Biotechnology (RNAi Therapeutics)
$11.50
▲ 5.99%
MCap $545M
Self-fetched today (no live-prices.json cache yet). Up 5.99% today and near the 52-week high, continuing a sustained run-up ahead of the August 2026 Phase 2 SANRECO topline data for divesiran in polycythemia vera.
BusinessRNAi therapeutics · divesiran (SANRECO Phase 2) in polycythemia vera · topline data due August 2026
Thesis

This refresh needs to be honest: Silence Therapeutics has already run hard ahead of its own catalyst, and real upside has compressed well below this board's 200%+ bar. The stock has roughly doubled since this name was first picked two weeks ago (from ~$6-7 to $11.50), and the 7-analyst consensus of $29.17 now implies only +154% from here — real and broad, but no longer a clean moonshot on a strict basis. What hasn't changed: the SANRECO Phase 2 topline data for divesiran in polycythemia vera is genuinely due in August 2026, and this remains a real binary readout. The market has simply already priced in a meaningful chunk of the optimism ahead of the actual data.

📝 Primary Verdict · Core Holding
SPECULATIVEค่าขนม

ค่าขนม — small position only. Real catalyst still ahead (August SANRECO data), but the stock already ran hard into it and upside has compressed accordingly.

82
score / 100 ⓘ
⚡ Catalyst
🧬 SANRECO Phase 2 Topline (Divesiran)~2-6 WEEKS

Topline data for the Phase 2 SANRECO study of divesiran 6mg in phlebotomy-dependent polycythemia vera patients, due August 2026 — a real, near-term binary readout that the stock has been running up into.

Aug 2026
🎯 Entry Point
Entry 1
$11.50
Current price — near the 52-week high after a sustained run-up into the August catalystScale in (small)
Entry 2PREFERRED
$9–9.75
Below the recent run-up — best R/R if some pre-data profit-taking occursIf dips
Entry 3
$7.00
Deep dip — only on a broad biotech selloff before the dataDeep dip only
✅ Take Profit
TP1
Base — data reads modestly positive or mixed
$16.68
+45%
TP2
Bull — clean positive SANRECO data, hits toward the consensus range
$22.43
+95%
TP3 🌙
Moon — strong positive data confirms best-in-class potential, hits full consensus target
$29.17
+153.7%
🔴 Stop Loss
Tight Stop
Below the recent run-up base — thesis-neutral but pre-data momentum reversing
$8.5
-26.1%
Hard Stop
Deep breach — would suggest a negative pre-data signal or broad biotech capitulation
$6
-47.8%
Risk / Reward
From Entry 2 ($9.38 mid) tight stop vs TP2
4.5 : 1
⚠ Reasonable R/R but the easy re-rate has already happened once — this is a smaller second bite, not a fresh discovery
📅 Estimate Date
SANRECO Phase 2 Topline
Binary readout the stock has already run up into
Aug 2026
Positive/negative on the primary endpoint
📈 Possible Up % — Scenario Spread
Bear
-35%
$7.48
Base
+45%
$16.68
Bull
+95%
$22.43
Moon
+153.7%
$29.17
← downsideupside →
🏛️ Fed / Macro Risk — LOW

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
Fed holds at 3.50–3.75%, but new Chair Warsh's hawkish tone has 9 of 18 officials projecting a further 2026 hike, with the next FOMC decision Jul 28–29, 2026.
Inflation
Core inflation remains above target and the 10-year yield sits near 4.48% — a modest headwind for small-cap biotechs generally.
Sector Impact
The SANRECO Phase 2 data readout is entirely macro-independent — clinical trial results don't respond to interest rates.
Summary
LOW — this is one of the more macro-independent names on the board since the near-term catalyst is a pure clinical data readout.
🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Consensus (7 analysts)
Buy$29.17+154%
H.C. Wainwright (outlier)
Buy$75+552%
current price $11.50
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

SLN✅ GoodJul 2026
+90%
in 8 days
Sustained run-up from ~$6-7 to $11.50 ahead of the August SANRECO data
Same-company precedent showing this stock has already captured significant pre-data optimism, the key context for sizing this refresh.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-26% / -40%) only when trading the earnings spot — not for the core holding (use the -26.1% / -47.8% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
roughly +90% to +100% over the two weeks prior to this reportsustained multi-week runup into the data readout, atypical for this cohort

SLN has shown a real, sustained pre-data runup this cycle — roughly doubling over the two weeks since it was first picked, in anticipation of the August SANRECO readout, a different pattern from names that show minimal pre-event drift.

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +40%
range: +20% to +60%· estimate given the pre-data runup already observed
Given the stock has already priced in significant optimism ahead of the data, a positive readout would likely still drive a real move but proportionally smaller than if the stock were still at its prior lows.
❌ Catalyst Missavg -40%
range: -30% to -55%· general small-cap biotech pattern, amplified by the pre-data runup
A disappointing Phase 2 readout after this much pre-data run-up would likely produce an outsized reversal, giving back a large portion of the recent gains on top of the standard negative-data reaction.
💼Spot Position Sizing
How the recommended % is derived
2%
of portfolio

Small-cap ($545M) that has already run hard into its own binary catalyst — 2% sizing reflects the reduced margin of safety compared to when this name was first picked near its lows.

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-26%($8.5)
Below the recent run-up base — thesis-neutral but pre-data momentum reversing
After Catalyst (Bad Result)-40%
A negative or ambiguous SANRECO readout would likely reverse much of the recent run-up — exit
📎 Sources

Generated 2026-07-22 · Not financial advice